Enanta in focus ahead of mid-stage trial data for RSV antiviral

Enanta Pharmaceuticals has scheduled a conference call to discuss mid-stage trial results for zelicapavir, an antiviral candidate targeting respiratory syncytial virus (RSV) infections, set for 8:30 a.m. ET on Monday.

Following the announcement of topline results from the RSVHR study, which focused on the efficacy of zelicapavir in high-risk adults, Enanta's stock rose around 17% in after-hours trading.

The Phase 2b study involved 186 high-risk adult participants, including those aged 65 and older and individuals with chronic health conditions, and enrollment for the trial was successfully completed.

Recommendation Rating: Strong Buy

Enanta Pharmaceuticals (NASDAQ:ENTA) has scheduled a conference call for Monday at 8:30 a.m. ET to share results from its mid-stage trial of the antiviral candidate zelicapavir, which targets infections caused by the respiratory syncytial virus (RSV). Following the announcement of the topline readout from the RSVHR study—aimed at assessing zelicapavir's efficacy in high-risk adults—Enanta's shares surged approximately 17% in after-hours trading on Friday.

The Phase 2b study enrolled adults at high risk for complications associated with RSV. This group includes individuals aged 65 and older, as well as those with chronic health conditions such as asthma and congestive heart failure. Last month, Enanta confirmed its intention to release initial data from this placebo-controlled trial in September, announcing that enrollment was successfully completed with a total of 186 adults participating.